Wednesday, September 2, 2009

Microarray Patent News

Arrayit Lands Patent for Population Scale Diagnostics in World's Most Populous Country

China Is Expected to Be a 'Diagnostics Business Bonanza' for Arrayit

SUNNYVALE, CA--(Marketwire - September 2, 2009) - Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces that on August 31st, 2009 the company received a patent certificate from the most populous country on the planet, the People's Republic of China. The patent covers Dr. Mark Schena's microarray methods of genotyping multiple patient samples, commonly referred to as Arrayit's "Variation Identification Platform™" (VIP) technology.
Arrayit VIP is a universal platform for deoxyribonucleic acid (DNA)-based genetic screening, testing, diagnostics, genotyping and single nucleotide polymorphism (SNP) analysis. In simple terms, VIP allows clinical laboratories to examine DNA samples from as many as 80,000 individuals with a single test rather than relying on limited "one test per patient" techniques. China is the world's largest marketplace, and Arrayit sees nearly unlimited diagnostics sales potential in this emerging region.
"VIP is well suited for analyzing DNA from large populations in a rapid, affordable and highly accurate manner," states Rene Schena, CEO and co-founder of Arrayit Corp. "We look forward to introducing VIP technology to the People's Republic."
VIP is a versatile testing platform that allows scientists and medical doctors to screen mass numbers of humans for the presence of genetic markers, as well as for viral and bacterial infections. VIP also empowers the analysis of livestock, poultry and crop plants. This is a very critical aspect of VIP, as it allows the tracing of disease origins from agents such as the H1N1 flu strain. VIP could clearly become the gold standard for genetic and infectious disease detection and management.
Arrayit has obtained VIP patents in a long list of countries, and the China issuance represents a significant milestone for the company.

About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.